findmyKOL

Scott McHam, DO

Basic profile

Hematology / Oncology

ORCIDNone on fileNPI
RegionLincoln, NE · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2004Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Scott McHam is an Oncology physician. OpenAlex indexes 6 publications with 335 citations (h-index 3).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
6publications

Distinct works indexed by OpenAlex.

335citations

Total citations across indexed works.

3h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
47companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

4101 Tiger Lily Rd Ste 100
Lincoln, NE 685165587

Telephone

402-420-7000

Provider last certified this registry record 16 Mar 2024.

View the NPPES registry record

Industry payments

47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    43.7%
    PD-1 inhibitor21.7%
    Pembrolizumab68%Nivolumab33%
    Part B, office-administered25 patients
    Platinum-based Drug9.6%
    Oxaliplatin96%Carboplatin4%
    Part B, office-administered37 patients

    + 8 more classes in this area

  • Blood & clotting

    34.3%
    Erythropoiesis-stimulating Agent19.3%
    Darbepoetin alfa100%
    Part B, office-administered21 patients
    Iron, parenteral preparations15%
    Ferric carboxymaltose100%
    Part B, office-administered22 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    9.9%
    Other antiemetics7.5%
    Fosaprepitant100%
    Part B, office-administered43 patients
    Serotonin-3 Receptor Antagonist2.4%
    Palonosetron hcl68%Granisetron hydrochloride18%Palonosetron hydrochloride12%Ondansetron Hcl3%
    Part D + Part B93 patients

    + 3 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”